India's pharmaceutical sector has emerged as the standout performer in 2026, with the sectoral index rising 27% year-to-date, significantly outperforming its closest competitors. According to The Economic Times, Capital Goods/Defence and Transport & Logistics sectors have gained 14% and 13% respectively, while Power/Coal advanced 8%. The pharmaceutical sector's outperformance is particularly notable given that several sectors remain under pressure, with Oil Marketing Companies declining 25%, Oil & Gas falling 20%, and IT Services shedding 17%. As reported by The Economic Times, Thomas V Abraham from Mirae Asset Sharekhan noted that Q2 FY27 results so far confirm that the sector has moved past its inflection point, with margins surprising positively. The phase-out of high-margin drugs like gRevlimid has been smoother than expected, making earnings far more predictable from here.
Laurus Labs has emerged as the biggest outperformer with shares surging 112% year-to-date, followed by Gland Pharma with a 78.08% gain and Sai Life Sciences advancing 69.78%. As reported by The Economic Times, Divi's Laboratories has delivered a 55.58% return, while Aurobindo Pharma gained 42.33%. The strong momentum has extended to Piramal Pharma, which rose 39.32%, followed by Ipca Laboratories at 37.42% and Zydus Lifesciences at 35.67%. However, several pharmaceutical stocks have underperformed, with Lupin declining 5.36% YTD, Alkem Laboratories falling 6.38%, and Cipla and Biocon losing 8.22% and 9.95% respectively. According to The Economic Times, Wockhardt has gained 31.14%, Ajanta Pharma and Torrent Pharmaceuticals have advanced 22.66% and 19.35% respectively, while Glenmark Pharmaceuticals has risen 17.04%.
Domestic formulations have provided a strong earnings anchor for major pharmaceutical companies. According to The Economic Times, Sun Pharmaceutical Industries reported 17.3% growth in its India formulations business, supported by volume growth of 6.7%. Dr Reddy's Laboratories' India revenue increased 17%, while Lupin reported growth of 14.7%. New product launches, including semaglutide, are creating additional opportunities for market share gains. In the US market, companies are benefiting from the phase-out of high-margin drugs like gRevlimid, with Sun Pharma's revenue excluding gRevlimid increasing 15% year-on-year and EBITDA rising 21%. The impact of the gRevlimid base reset is increasingly behind the sector, while underlying businesses are showing signs of improvement.
The contract development and manufacturing organisation (CDMO) segment has been the standout performer, benefiting from strong growth and improving operating performance. As reported by The Economic Times, Laurus Labs exceeded expectations, reporting record revenue of ₹2,206 crore, up 33% year-on-year, with CDMO revenue surging 75% to ₹904 crore. Its EBITDA margin expanded to 34.5%. Piramal Pharma also reported healthy growth, with CDMO revenue increasing 36% to ₹1,424 crore. Thomas V Abraham from Mirae Asset Sharekhan noted that CDMO has been the standout segment, with encouraging concall commentary on enquiries and capex plans of CDMO firms. The opportunity arising from $200-300 billion worth of drugs going off patent over the coming years provides significant growth runway for the CDMO segment. However, following the sharp year-to-date rally, further upside in these stocks is likely to depend more on earnings growth than on additional valuation re-rating.
Analysts remain cautiously optimistic about the pharmaceutical sector's prospects, though they advise exercising caution regarding potential market volatility. According to The Economic Times, Thomas V Abraham from Mirae Asset Sharekhan emphasized that the concall commentary on enquiries and the capex plans of CDMO firms are encouraging, while cautioning that investors should be prepared for some volatility in quarterly performance given the inherently lumpy nature of CDMO contracts. V K Vijayakumar from Geojit Investments cautioned that while the sector has been performing well, sustainability will depend on broader market recovery. He believes FIIs are likely to favour sectors at more attractive valuations, making pharmaceuticals less compelling than financials or capital goods. The sector's improved earnings visibility and defensive characteristics make it attractive in uncertain times, but investors should be prepared for volatility given the lumpy nature of CDMO contracts.
